MARKET

MRTX

MRTX

Mirati
NASDAQ

Real-time Quotes | Nasdaq Last Sale

119.00
+1.62
+1.38%
Closed 16:16 07/08 EDT
OPEN
118.02
PREV CLOSE
117.38
HIGH
119.49
LOW
115.58
VOLUME
342.14K
TURNOVER
--
52 WEEK HIGH
132.59
52 WEEK LOW
66.01
MARKET CAP
5.19B
P/E (TTM)
-18.3021
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MRTX stock price target is 118.07 with a high estimate of 152.00 and a low estimate of 68.00.

EPS

MRTX News

More
MRTX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Mirati Therapeutics, Inc. and Encourages Investors to Contact the Firm
PR Newswire · 2d ago
2 Biotech Stocks That Could Soar in 2020
MotleyFool.com · 07/01 11:12
Morgan Stanley Bets on These 3 Stocks
TipRanks · 06/17 16:00
Nvidia, Intel stocks get downgraded at Morgan Stanley
MarketWatch · 06/16 15:09
The 7 Best Semiconductor Stocks on the Market Now
InvestorPlace · 06/12 16:54
Mirati (MRTX) Up 4.1% Since Last Earnings Report: Can It Continue?
Zacks · 06/06 16:31
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
PR Newswire · 06/05 14:00
Chip Stocks Rally Despite USChina Tensions
Investopedia · 06/03 14:45

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About MRTX

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit KRAS G12C mutations which are present in non-small cell lung cancer (NSCLC) adenocarcinoma patients, colorectal cancer (CRC) patients, pancreatic cancer patients, as well as several other difficult-to-treat cancers. Sitravatinib is a spectrum-selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
More

Webull offers kinds of Mirati Therapeutics Inc stock information, including NASDAQ:MRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRTX stock methods without spending real money on the virtual paper trading platform.